All Articles
Updated results from the phase 2 KRYSTAL-7 study continue to highlight the potential of first-line adagrasib (Krazati; Bristol Myers Squibb) combined with pembrolizumab (Keytruda; Merck) in patients with advanced or metastatic KRAS G12C–mutated non–small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) tumor proportion score of ≥50%. Read More ›
Study results presented at the European Lung Cancer Congress 2025 demonstrate the role of osimertinib (Tagrisso; AstraZeneca), as monotherapy across stages and settings of EGFR-mutated non–small cell lung cancer. Read More ›
The evolution of precision medicine has transformed oncology, offering targeted treatment strategies tailored to individual patients. However, for many healthcare practitioners, effectively applying precision medicine in clinical practice remains a significant challenge. Read More ›
At the Hematology/Oncology Pharmacy Association 2025 Annual Conference, Oncology Practice Management spoke with Iman Ahmed, PharmD, BCOP, Clinical Pharmacist Specialist, Ambulatory Hematology, at the University of Michigan, Rogel Cancer Center, Ann Arbor, MI, about how social determinants of health affect health inequities in hematologic malignancies and the provider’s role in mitigating these disparities, including research, advocacy, and the development of oncology-specific tools. Her data were presented at the conference.
Read More ›Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups. Read More ›
Patients waited an average of 2+ months and up to 16.8 months to receive
their medication. Read More ›
Privacy and Security Guidance for the Medical Practice HIPAA gives patients many rights with respect to their health information. Read More ›
Research has shown that when patients receive care from providers who share similar racial or ethnic backgrounds, their health outcomes tend to improve. Read More ›
Despite their therapeutic potential, the adoption and utilization of bispecific antibodies exhibit significant disparities, particularly between urban and rural healthcare settings. Read More ›
Officials with the FDA have approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig; Bristol Myers Squibb) for subcutaneous injection across approved adult, solid tumor nivolumab indications as monotherapy, monotherapy maintenance following completion of combination therapy. Read More ›